HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1
PLYMOUTH MEETING, Pa., Dec. 7, 2023 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY) today announced positive topline results from its Phase 2 signal detection study evaluating the safety and efficacy of pitolisant in adult patients with myotonic dystrophy type 1 (DM1).
Related news for (HRMY)
- harmony biosciences holdings, inc. announces pricing of public offering of common stock by selling shareholders
- harmony biosciences holdings, inc. announces commencement of proposed public offering of common stock by selling shareholders
- HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024
- HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE
- HARMONY BIOSCIENCES TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE